BRKR Quote, Financials, Valuation and Earnings

Avantor has a net margin of 1.4% compared to Bruker's net margin of 29.67%. Bruker's return on equity of 6.78% beat Avantor's return on equity of 12.92%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 87.65%. On the other hand Avantor has an analysts' consensus of $24.16 which suggests that it could grow by 59.7%. Given that Bruker has higher upside potential than Avantor, analysts believe Bruker is more attractive than Avantor.

Bruker has a beta of 1.184, which suggesting that the stock is 18.426% more volatile than S&P 500. In comparison Avantor has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.603%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.55%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are smaller than Avantor quarterly revenues of $1.7B. Bruker's net income of $13.7M is lower than Avantor's net income of $500.4M. Notably, Bruker's price-to-earnings ratio is 47.97x while Avantor's PE ratio is 14.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.62x versus 1.52x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Azenta has a net margin of 1.4% compared to Bruker's net margin of -9.04%. Bruker's return on equity of 6.78% beat Azenta's return on equity of -7.97%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 87.65%. On the other hand Azenta has an analysts' consensus of $55.60 which suggests that it could grow by 90.93%. Given that Azenta has higher upside potential than Bruker, analysts believe Azenta is more attractive than Bruker.

Bruker has a beta of 1.184, which suggesting that the stock is 18.426% more volatile than S&P 500. In comparison Azenta has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.003%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.55%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Azenta quarterly revenues of $147.5M. Bruker's net income of $13.7M is higher than Azenta's net income of -$13.3M. Notably, Bruker's price-to-earnings ratio is 47.97x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.62x versus 2.26x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 1.4% compared to Bruker's net margin of -107.24%. Bruker's return on equity of 6.78% beat Bio-Rad Laboratories's return on equity of -23.87%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 87.65%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $365.00 which suggests that it could grow by 61.79%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bruker has a beta of 1.184, which suggesting that the stock is 18.426% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.924%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.55%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Bruker's net income of $13.7M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Bruker's price-to-earnings ratio is 47.97x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.62x versus 2.48x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of 1.4% compared to Bruker's net margin of 12.98%. Bruker's return on equity of 6.78% beat Revvity's return on equity of 3.45%.

Bruker has a consensus price target of $68.42, signalling upside risk potential of 87.65%. On the other hand Revvity has an analysts' consensus of $140.38 which suggests that it could grow by 48.02%. Given that Bruker has higher upside potential than Revvity, analysts believe Bruker is more attractive than Revvity.

Bruker has a beta of 1.184, which suggesting that the stock is 18.426% more volatile than S&P 500. In comparison Revvity has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.796%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.55%. Revvity offers a yield of 0.3% to investors and pays a quarterly dividend of $0.07 per share. Bruker pays 26.7% of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $979.6M, which are larger than Revvity quarterly revenues of $729.4M. Bruker's net income of $13.7M is lower than Revvity's net income of $94.6M. Notably, Bruker's price-to-earnings ratio is 47.97x while Revvity's PE ratio is 42.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.62x versus 4.23x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.